Oz Azam, Empyrean Neuroscience CEO
October 18, 2022 11:37 AM EDTUpdated 01:40 PM
R&D

Where CAR-Ts were in 2012? For­mer Tmu­ni­ty CEO Oz Azam un­veils not-quite-a-psy­che­delics biotech

Lei Lei Wu

News Reporter

In Feb­ru­ary, Oz Azam left Tmu­ni­ty months af­ter its cell ther­a­py pro­gram came to a screech­ing halt fol­low­ing two pa­tient deaths. At the time …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times